Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wasn't 100% sure if the formulation was the same. If it was, would they even be allowed to do trials as it would be a violation Pfizer's patent? Pulled this from GHLV website about X-excite. I feel it has been changed as it used to state something about Viagra. Also all the EU trials were in comparison to Viagra, will have to double check about the formulation.
Erectile dysfunction is a physical condition that affects 10% of men worldwide. The current treatment is the use of drugs that prevent the enzyme 5-phosphodiesterase. Most notable products of this class are Sildenafil, Tadalafil, and Vardenafil, collectively generate over $3 billion annually. All of them carry a considerable side effects due to gasteric and colonic absorption, these include acidoses(gas build up), stol run, and many more. New formulation of these products are developed by us which bypassess all the gasterointestinal side effects, making the drug far more patient friendly and desirable.
About Sublingual Technology
The Company's drug formulation is designed to enhance the delivery of the medical products faster to the body than current oral formulations. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane (tissues of the mouth) quickly. This technology works well for drugs that need faster results and have major side effects associated with gastrointestinal and/or liver break down. It is scientifically accepted that the sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection.
There's a reason we are consistently popping up on the breakout boards without any news releases http://investorshub.advfn.com/boards/hotboardsrelative.aspx
People are interested in the product and the upside. It's all about speculation here. I am sure GHLV is on a lot of watch lists and people will pick their time to enter. Cant have sellers without buyers. If we do get that meaty piece of news in a few months time, I think it has the potential to skyrocket in one day's session. IMO.
Lack of innovation is the key! Also, is the formula similar or exact of Viagra? Does it violate the patent? I don't think we know. There are many erectile medicines on the market. For all we know GHLV has their own that hasnt infringed on any patents. Besides, the key patent is The sub lingual! The common factor in all GHLV products.
I'd love the opportunity to even pay capital gains tax! That means I sold for a profit. And I ain't selling for a long time! Go VPRO. Put that new PR company to use!
Agreed. I have learnt from this that pennies should be traded, not invested in. Looking back if I analyzed the long term picture better I would have seen that capital needed to be raised and dilution may occur, therefore allowing a better entry point. Oh well. Only been "investing" or trading for five months. So lesson learned. Still think there is valuable technology in the Hands of GHLV. Long and strong, although a bit battered.
Well just remember GHLV is primarily being run by doctors. I am hoping that his focus is more on the success of the products as opposed to the daily pps. I think he sees this as a company that will trade at much higher levels once the trials are complete. I do believe Dr S transfered many shares to his daughters. Is this correct? If so, he also wouldn't want the pps to stay at this level. His main goal is still to have a successful product/technology, which in turn will bring more serious eyes to GHLV.
Well how did you think GHLV would raise capital for all their endeavors? They are a penny for a reason. Bank won't give them funding on a whim.
Also I was curious as to how a company can replicate a patented formulation and still be approved for clinical trials, ie Viagra. Anybody know the answer to this? I'm assuming the X-excite's formulation differs enough to where it wouldn't violate this. I am personally hoping for licensing deals of the sublingual technology once we received good news after trials. Don't forget all the other drugs as well.
One would think with all this selling people have to be buying? Meaning that people do see a future for this and they have picked a good entry point. I also got in at .06 but avg down when I can because I still have faith in the direction as in my mind, nothing has changed over the past few months.
I think this extract has some weight, as we do not know the exact formula of X-excite. Plus, as you stated before, the sublingual technology is key and guess who owns the patents.
"Yet Pfizer likely won't be able to retain all Viagra sales. Viagra shares the same active ingredient as Pfizer's Revatio treatment for pulmonary arterial hypertension, which is due to lose patent protection next year. Some doctors are expected to prescribe generic Revatio for erectile dysfunction, even though the doses are slightly different than Viagra. "
Yes hopefully this leads to full transparency.
Were we expecting the 10-Q to be for 2010??
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8130293
It would be great to see VPRO break and hold the 50DMA with a 4th green candlestick in a row. MACD is on verge of a crossover, possibly end of week.
Nice post. If you click "SHARE" underneath the chart you can clink IHub and get a linkable version below. Let's see the par sar confirm another day of support and hopefully the Stochastic and MACD will cross north indicating a possible run. I could be wrong but I think the par sar can give false signals while a stock is in consolidation mode. Im still new to TA but the Doc would probably know best. I'd prefer substantial news however!
VPRO - Daily Candlesticks
How is this not illegal??? Front load and then pay a newsletter as a non-affiliated 3rd party for an "awareness" newsletter?
Company: Global Earth Energy Inc. NEW (GLER)
End of Day: $ Close: 0.004 Volume: 142,747,330
$ Change: 0.000 % Change: 0.000
Dollar Volume: 528,165
3 Month : $ High 0.005 Volume 3m avg: 15,364,323
$ Low: 0.003 % Change 3m: 0.036
Dollar Volume 3 m: 51,010
Compensation:
Wise Alerts - none listed
Otc Tip Reporter - seven thousand five hundred dollars by a non-controlling third party for a one day investor awareness program.
Research driven investor - fifty thousand dollars cash by Endeavor llc , a non-affiliated third party to profile GLER for a one day investor relations campaign.
OTC Picks Publisher - none listed
Also didn't we just get a PR about them using a PR service? I don't need updates on guest speaking but something meaty and I am willing to wait. I am sure they are getting their ducks in a row with the financials so from here on out, it will be an easier process.
Here it is... http://stockreads.com/Stock-Newsletter.aspx?id=49806
Dear Fellow Investors, Coming off our latest big winners we couldn`t be more excited to keep the momentum going into our newest announcement. Our New Monster Pick is:
Global Earth Energy, Inc. (OTCBB: GLER) GLER is focused on building and operating green alternative energy technologies to aid the world`s energy crisis & help relieve the greenhouse effect! Immediately put GLER on your RADAR, not only do the technicals look unbelievable but it`s in a very attractive sector right now and is a GREEN PLAY! Realize, now more than ever Americans are beginning to look to themselves to secure the nations` Energy needs. We want more efficient, economical and sustainable energy sources to protect our pocketbooks now and the environment for our children in the future.
GLER believes in a diversification strategy to ensure Americans win in both of these areas, and by doing so is positioning itself as a future leader in Renewable and Recoverable Energy Markets. Solar Energy, wind energy, Coal, Oil and Gas Recovery are critical areas of growth and development in the United States.
GLER also focuses to operate a ONE MILLION gallon per year Biodiesel Pilot Plant, while expanding into the Parallel Solar and Wind Turbine Energy markets! GLER is also vigorously pursuing joint ventures with top independent operators in the Solar and Recovery Oil and Gas markets.
By securing more partnerships could ensure maximum returns for shareholders while deferring some of the costs of an initial investment.
In Fact...One of GLER`s subsidiaries is a Huge American Solar Company RCI Solar Realize, this isn`t your typical GREEN PLAY focusing on only one alternative energy... GLER is diversified into multiple green technologies! Here is one of their subsidiaries in the HOT Solar Sector! Wholly-owned subsidiary RCI Solar:
RCI Solar Inc., a North American provider of renewable energy products and services.
GLER will operate the business of RCI Solar Inc. from its facility located in Vancouver, British Columbia, Canada.
RCI Solar provides renewable energy products and services to residential and commercial markets in North America.
The Company sells complete turnkey renewable energy solutions based on three core products: Solar Domestic Hot Water, Solar Photo Voltaic (PV) Panels and AQUA III Heating & Cooling System. Along with these products, RCI Solar supplies a wide variety of fan convectors, solar storage tanks, controls, inverters, and ancillaries.
Here are some current projects:
Global Earth Natural Resources / Modern Coal Joint Venture Global Earth Natural Resources Inc.`s business lines include natural resources for multiple end use purposes, including Coal and other Minerals. The coal mines are located on approximately 5,000 acres near Hindman, Kentucky. This area is considered one of the largest coal producing regions in the United States today. The nearby counties account for approximately 75% of the coal produced in Kentucky and approximately 12% of the coal produced in the United States. The acquisition by Global Earth Natural Resources, L.L.C. is expected to consist of three existing mines that produce a very clean, high-quality steam and metallurgical coal. The coal is produced using surface and subsurface mining operations.
Global Earth/ReFlora De Brazil Joint Venture Global Earth and ReFlora are very sensitive concerning the environment. Global Earth and ReFlora over 300,000 hectares of tropical forests in Brazil. We believe that tropical forest preservation is very important for the global climate. The joint venture has hired a management team with global expertise managing over 21,000,000 hectares.
Global Earth and ReFloras eco-system business opportunities include but are not limited to:
Development and sale of carbon off-set credits based on current rain forests and agricultural conditions existing in Brazil.
Development and sale of carbon off-set credits generated from forest set-aside (avoided deforestation) projects in appropriate locales in Brazil.
Development and sale of REDD and VER carbon credits generated from rain forests in Brazil.
Development and sale of water abatement, biodiversity, and conservation credits.
Controlled sustainable production and sale of agricultural products including timber and bio-fuel crops.
Global Earth/LifeCycle Joint Venture:
http://clicks.aweber.com/y/ct/l=MJcBt&m=3mkpsrRkBqG1RB1&b=9pXOax9zIPQai.CYCH.2Pg The joint venture will own and manage $12 Million in settlements. LifeCycle will continue to assemble portfolios of life settlements using its network of aggregators and brokers, which include some of the largest leading life settlement aggregators in the US. In pricing life settlements for possible acquisition by LifeCycle, LifeCycle will continue to use its successful proprietary pricing and bidding models.
These models and strategies spread risk and will, going forward, continue to spread risk over large numbers of life settlements covering insurers with varying life expectancies and medical conditions and residing in diverse parts of the U.S. in order to reduce a negative impact which any one particular life settlement might have on the life settlement portfolio if which it is a part.
Therefore, any unexpected aberration in an Insured`s life expectancy is expected to have a minimal impact on the respective portfolio to which that life settlement is allocated. The amount paid for each life settlement will be negotiated and such amounts offered to be paid for such life settlements will be based on LifeCycle`s proprietary pricing and acquisition models and strategies. The life settlements will be comprised of life insurance policies issued and underwritten by life insurance companies having an "A" or better rating or its equivalent from one or more nationally recognized rating services (e.g., Moody`s, A.M.
Best, Standard & Poor`s).
GLER looks like it`s setting up for a huge breakout ! WE ARE ISSUING A STRONG ALERT!!! As always we encourage subscribers to do their own due diligence and visit the company website: http://clicks.aweber.com/y/ct/l=MJcBt&m=3mkpsrRkBqG1RB1&b8la68AepwWVukTiwKMdQ As always do your own research, book profits when you are in a position to do so, and always trade with stop loss orders to protect yourself if the trade goes against us.
Sincerely, The OTCtipReporter.com Team DON`T MISS ANOTHER HOT OPPORTUNITY TO MAKE HUGE PROFITS! GENERAL NOTICE AND DISCLAIMER - PLEASE READ CAREFULLY The companies that are discussed on OTCtipReporter.com have not approved the statements made. This opinion contains forward-looking statements that involve risks and uncertainties. A company`s actual results could differ materially from those described in any forward-looking statements or announcements discussed herein. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OTCtipReporter.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Nor are any of its officers, affiliates, or employees. Please consult a broker before purchasing or selling any securities viewed on OTCtipReporter.com or mentioned herein.
Affiliates, officers, directors and employees of OTCtipReporter.com may have also bought or may buy shares of companies mentioned herein and may profit in the event those shares rise in value.
OTCtipReporter.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make their own decision based on his or her judgment of the market. This advertisement is not a solicitation or recommendation to buy, sell or hold securities and does not provide an analysis of the financial position of the company. We recommend you use the information found in this advertisement as an initial starting point for conducting your own research on the advertised company in order to determine your own personal opinion of the company before investing. All statements and opinions contained in this advertisement are the sole opinion of the authors and are subject to change without notice. We are not liable for any investment decisions by our readers. Readers should independently investigate and fully understand all risks before investing. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. We are not registered investment advisers, or broker-dealers, or members of any financial regulatory bodies. Furthermore, our associates and/or employees and/or principals may have stock positions in advertised companies purchased in the open market or in private transactions. These positions may be liquidated, without prior notification, even after we have made positive comments regarding the advertised company. The receipt of this information constitutes your acceptance of these terms and conditions. Reading this advertisement shall not create under any circumstances an offer to buy or sell stock in any company advertised. Nor shall it create any principal-agent relationship between the reader and us. Void where prohibited. Information within this advertisement contains "forward looking" statements within the meaning of Section-27(a) of the U.S.
Securities Act-of-1933 and Section 21(e) of the U.S. Securities Exchange Act-of -934. Neither OTCtipReporter.com, its officers, affiliates, or employees is a broker-dealer. The information on OTCtipReporter.com, including the opinions expressed and the statements made within, is for informational and advertising purposes only and should not be construed as investment-advice, and does not constitute an offer to sell any securities, nor is it to be construed as a solicitation to purchase any securities in any state or other jurisdiction where the offer or sale is not permitted. The information to prepare this report is believed to be from reliable sources, but no representation is made as to the accuracy or completeness of such information. Investment in securities carries a high degree of risk and involves risks and uncertainties, which may result in investors losing all of their invested capital. Past performance does not guarantee future results.The information contained herein contains "forward-looking statements," within the meaning of Section-27A of the Securities Act-of-1933 and Section 21E of the Securities Exchange Act-of-1934.
Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other key personnel, and other risks detailed in the reports filed with the Securities and Exchange Commission by the companies who are mentioned in this periodical. Readers should consult with their own professional investment, tax and portfolio advisors before making any investment decision and should independently verify all information herein.
More complete information about any of the companies mentioned in this periodical is available from the website of the Securities and Exchange Commission, at sec.gov, and copies of their filings may be read without charge and copies obtained at prescribed rates from the public reference facilities of the Commission, at 450 Fifth Street, NW, Washington, DC 20549.
Buying and Selling of Shares OTCtipReporter.com intends to sell its shares. OTCtipReporter.com may sell its shares for less than target prices given in opinions.
OTCtipReporter.com affiliates, officers, directors and employees may have also bought or may buy the shares discussed in this report and may profit in the event those shares rise in value.
OTCtipReporter.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. There are risks involved Always remember that OTCtipReporter.com are not analysts and investing in securities such as the ones listed within are for high risk tolerant individuals only and not the general public. Whether you are an experienced investor or not you should always consult with a broker before purchasing or selling any securities viewed on OTCtipReporter.com. If at any time you wish to be removed from our list simply
Read more: http://stockreads.com/Stock-Newsletter.aspx?id=49806#ixzz1WUKyOQFo
Go check out the link. Just a measurement really of what boards are receiving activity. Same with the Buzz Cloud. Climbed up a few spots as well.
GHLV just popped up on the Breakout Boards. More eyes http://investorshub.advfn.com/boards/hotboardsrelative.aspx
I Avg down again today finally. Long term picture is still there, as are their patents for sublingual technology.
News for 'BRZL' - (Brazos International Exploration terminates agreement to acquire Renfro Energy Deal In Brief)
Aug 24, 2011 (Datamonitor Financial Deals Tracker via COMTEX) -- Brazos
International Exploration, Inc., a mineral property exploration company, has
terminated its agreement to acquire Renfro Energy, LLC (RE), an oil and gas
company. Both the companies are based in the US.
Update on March 29, 2011:
Brazos International has obtained a one month extension to acquire RE.
Update on March 10, 2011:
Brazos International has executed a definitive purchase and sale agreement to
acquire RE.
The transaction is scheduled to occur on or before March 31, 2011.
Announcement (May 17, 2010):
Brazos International has signed a letter of intent to acquire RE in an all cash
transaction.
Under the terms of the agreement, in exchange for cash consideration and a net
profits interest in the property, Brazos International will purchase 100% of the
membership interests in RE which includes its two producing oil wells making
12-15 barrels per day, one saltwater disposal well, one shut-in well designated
for exploration drilling, several pumping units, an oil, gas, and water
separation facility, an oil and water pumping facility, an oil and gas storage
facility, and five square miles of 3-D Seismic data processed and partially
evaluated.
Deal Type Acquisition
Sub-Category Majority Acquisition
Deal Status Terminated: 2011-08-19
Deal Participants
Target (Company) Renfro Energy, LLC
Acquirer (Company) Brazos International Exploration, Inc.
Deal Rationale
The acquisition will enable Brazos International to generate significant cash
flow and increase shareholder value.
(c) 2001-2007 Datamonitor. All rights reserved. Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon.
-0-
Source: Comtex Wall Street News
Compliments of Scottrade.com
That person is also probably sitting on the bid trying to flip. Hope they get caught and have to watch from the sidelines!
Last trade $27 minus commissions. WEAK.
Seems like our bid whackers still here. Shocker.
#7 on the BB and on the 24hr buzz cloud. More eyes on us. Solid SWME
http://investorshub.advfn.com/boards/hotboardsrelative.aspx
Heating up my man, heating up! Scrounged some more funds just waiting to clear and I will add more to my nice little position. Looking strong here. #11 on BB http://investorshub.advfn.com/boards/board.aspx?board_id=3357
.0055x.0056
On the advancers tab http://www.otcmarkets.com/home
.078! +212%
IDCX .032x.089
.032x.089
Still no L2. The free trial never allowed it and Scottrade wants to charge me monthly for it so I said no thanks. Feel free to post!
.0035x.004 Here we go! Even with the whackers, it always snaps back up. Giddy up SWME
Trying to accumulate as much as I can before this pops.
Good to see you in this. I was away yesterday and saw that somebody got more cheapies yesterday! Lousy bid whacker.
haha thank you!
Glad i stayed away from that!
People holding tight. On the bid at .034 and no fill! Grrrrr. Wish I could have scooped those .0019s
You in on GVDI?